19.6 C
Sunday, May 26, 2024

(CSE: AYUR) Ayurcann Undervalued, Positioned to Grow

Ayurcann Holdings Corp (CSE:AYUR) is a leading Canadian B2B post-harvest solution integrated Canadian extraction company and provider focused on providing scalable oils and various derivative products. Setting its sights on becoming the partner of choice for leading Canadian cannabis brands by delivering best-in-class, proprietary services, including ethanol extraction, formulation, product development and custom manufacturing. Ayurcann offers an unparalleled investment opportunity that stands out from the rest.

The company’s leadership believes the sector is moving away from the early strategy of vertical integration. Right off the bat, enormous and all around supported first-movers like Canopy Growth and Aurora Cannabis looked to claim each cycle ‘from seed to deal’, buying more modest LPs along the supply chain. The excitement about the potential for legal cannabis was significant, and the amount of investment in the space was substantial. But vertical integration is a model rarely seen within the agricultural space. And with the initial wave of frenzied investment over, companies are forced to make every dollar count. In a period when mere proximity to the cannabis space is no longer enough to attract investment capital, companies like Ayurcann are seeing increasing upside in specialization.

Ayurcann has partnered with numerous cannabis brands for manufacturing and co-distribution purposes. Besides Fuego and Vida, the company has also partnered with Green Bee, an award winning cannabis producer, and Bazeleet Group, one of the largest medical cannabis producers in Israel, a hotbed for cannabis startups.


In its latest Announcement Ayurcann states that it has received its flower sales license amendment from Health Canada effective April 19, 2022. The Flower Sales License will allow Ayurcann to sell dried cannabis flower products in Canada through authorized distributors and retailers. Ayurcann Holdings Corp shares C.AYUR are trading at $0.155

Ayurcann  looks undervalued compared to its competitors and is positioned to build on a successful 2022-23

Related Articles


Please enter your comment!
Please enter your name here

Stay Connected
- Advertisement -spot_img



Latest Articles